# Ruxolitinib for Steroid-refractory GVHD

> **NCT02997280** · PHASE2 · COMPLETED · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 75 (actual)

## Conditions studied

- Graft Vs Host Disease

## Interventions

- **DRUG:** Ruxolitinib Oral Tablet

## Key facts

- **NCT ID:** NCT02997280
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2018-12
- **Final completion:** 2019-04
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2019-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02997280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02997280, "Ruxolitinib for Steroid-refractory GVHD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02997280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*